MetrioPharm Investor Relations News QI 2022

Outlook by the Chairman of the Board Rudolf Stäger

Dear shareholders

It is with cautious optimism that I, as Chairman of the Board of MetrioPharm AG, welcome the current rather positive turn of events in the Corona pandemic developments in Switzerland and Germany. Due to vaccination and other measures, the course of the Corona disease is noteworthy less devastating than it was only a year ago. MetrioPharm is currently conducting a clinical trial in COVID-19, which is funded by the European Commission under the iMPact project. Based on the results of this study, we expect to be able to make an additional contribution to the treatment and faster recovery of those suffering from SARS-CoV-2 virus. To date, more than 50 percent of the planned study participants have already been enrolled in MetrioPharm's Phase II study in COVID-19.

In the context of the relaxation of the Corona measures in Switzerland and Germany, we are particularly pleased to be able to hold this year's Annual General Meeting of MetrioPharm AG on June 23 again in person with you, dear shareholders, in Zurich. Here in particular your constructive contributions and suggestions have been missing in the past two years. An exchange that the Annual General Meeting forum offers us under normal circumstances. In this context, I also welcome a gradual return to normality.

The management of MetrioPharm AG, CEO Thomas Christély and CSO Dr. Wolfgang Brysch, will also resume their participation in events and congresses. Many of these events had been cancelled over the course of the past two years. For example, the company plans to participate in this year's BIO-Europe Spring 2022 in Basel from March 28 to 30, which will be once again held digitally this year. The MetrioPharm team will gladly keep you informed about developments in the current trial as well as participation in conferences and meetings in 2022 via our usual channels.

Kind regards
Rudolf Stäger
President of the Board

MetrioPharm AG at BIO-Europe Spring 2022 in Basel

Thomas Christély, CEO of MetrioPharm AG and CSO Dr. Wolfgang Brysch will participate in BIO-Europe Spring this year. Participation will be digital. Approximately 2500 key market players participate in BIO-Europe Spring each year. Among them are decision makers from the biotech and pharma sector, finance professionals, business development teams, investors and other industry experts.

MetrioPharm's iMPact project

In May of last year, MetrioPharm, together with its three consortium partners ImmunoLogik, Catalyze and MC Toxicology Consulting, applied for inclusion in the European Commission's HERA Incubator funding program. The iMPact project, which involves conducting a Phase II clinical trial with MetrioPharm's lead compound MP1032 against COVID-19, as well as preclinical studies on the effect of MP1032 on mutant variants of SARS-CoV-2 was selected for funding in July 2021. In November 2021, MetrioPharm signed a grant agreement for €7.9 million. More information about the iMPact project can be found here.


Your contact:

MetrioPharm AG Eva Brysch Investor Relations Managerin          

Lia Petridou
Corporate Communications & Press Relations

T +49 (0) 30 33 84 395 53
F +49 (0) 30 33 84 395 99
E press@metriopharm.com
W www.metriopharm.com



MetrioPharm AG Download PDF